AbbVie (NYSE:ABBV - Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 10.380-10.580 for the period, compared to the consensus EPS estimate of 11.990. The company issued revenue guidance of -. AbbVie also updated its Q3 2025 guidance to 1.740-1.780 EPS.
AbbVie Stock Performance
Shares of NYSE:ABBV traded down $2.50 during trading on Friday, hitting $234.07. 6,539,471 shares of the stock were exchanged, compared to its average volume of 6,498,375. AbbVie has a 1-year low of $163.81 and a 1-year high of $244.81. The company has a market capitalization of $413.49 billion, a price-to-earnings ratio of 111.46, a price-to-earnings-growth ratio of 1.43 and a beta of 0.51. The company's fifty day simple moving average is $209.90 and its 200-day simple moving average is $195.87. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74.
AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing the consensus estimate of $3.24 by ($0.27). The company had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.AbbVie's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the business earned $2.65 EPS. Sell-side analysts expect that AbbVie will post 12.31 EPS for the current fiscal year.
AbbVie Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Stockholders of record on Wednesday, October 15th will be given a dividend of $1.64 per share. The ex-dividend date is Wednesday, October 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie's payout ratio is presently 312.38%.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the company. Daiwa America upgraded AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 7th. Cantor Fitzgerald increased their price target on AbbVie from $215.00 to $245.00 and gave the company an "overweight" rating in a research report on Monday, September 15th. JPMorgan Chase & Co. boosted their price target on AbbVie from $200.00 to $235.00 and gave the company an "overweight" rating in a research note on Tuesday, September 16th. Raymond James Financial restated an "outperform" rating on shares of AbbVie in a research note on Monday, August 25th. Finally, HSBC set a $225.00 price target on AbbVie in a research note on Thursday. Four analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, AbbVie has an average rating of "Moderate Buy" and an average target price of $228.22.
Get Our Latest Research Report on ABBV
Insider Transactions at AbbVie
In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the sale, the executive vice president directly owned 177,292 shares of the company's stock, valued at $35,178,278.64. The trade was a 19.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Nicholas Donoghoe sold 13,295 shares of the business's stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the sale, the executive vice president directly owned 58,247 shares of the company's stock, valued at $11,562,611.97. The trade was a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is owned by insiders.
Institutional Trading of AbbVie
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ABBV. Rakuten Securities Inc. grew its holdings in shares of AbbVie by 26.5% in the second quarter. Rakuten Securities Inc. now owns 368 shares of the company's stock valued at $68,000 after acquiring an additional 77 shares in the last quarter. Binnacle Investments Inc grew its holdings in shares of AbbVie by 33.2% in the second quarter. Binnacle Investments Inc now owns 493 shares of the company's stock valued at $92,000 after acquiring an additional 123 shares in the last quarter. Darwin Wealth Management LLC bought a new position in shares of AbbVie in the second quarter valued at approximately $277,000. Redwood Financial Network Corp grew its holdings in shares of AbbVie by 10.8% in the second quarter. Redwood Financial Network Corp now owns 1,649 shares of the company's stock valued at $306,000 after acquiring an additional 161 shares in the last quarter. Finally, WFA of San Diego LLC bought a new position in shares of AbbVie in the second quarter valued at approximately $333,000. 70.23% of the stock is owned by institutional investors.
About AbbVie
(
Get Free Report)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
